SCOT
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. In total, 608...
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Publication date: | 2018 |
| Country: | España |
| Institution: | Universitat Autònoma de Barcelona |
| Repository: | Dipòsit Digital de Documents de la UAB |
| Language: | English |
| OAI Identifier: | oai:ddd.uab.cat:214575 |
| Online Access: | https://ddd.uab.cat/record/214575 https://dx.doi.org/urn:doi:10.1038/s41416-018-0319-z |
| Access Level: | Open access |
| Keyword: | Health care economics Economics Chemotherapy |
| _version_ | 1878740324243734528 |
|---|---|
| author | Robles-Zurita, José |
| author2 | Boyd, Kathleen A.|||0000-0002-9764-0113 Briggs, Andrew H. Iveson, Timothy Kerr, Rachel S. Saunders, Mark P. Cassidy, Jim Hollander, Niels Henrik Tabernero, Josep|||0000-0002-2495-8139 Segelov, Eva Glimelius, B. Harkin, Andrea Allan, Karen McQueen, John Pearson, Sarah Waterston, Ashita Medley, Louise Wilson, Charles Ellis, Richard Essapen, Sharadah Dhadda, Amandeep S. Hughes, Rob Falk, Stephen Raouf, Sherif Rees, Charlotte Olesen, Rene K. Propper, David Bridgewater, John Azzabi, Ashraf Farrugia, David Webb, Andrew Cunningham, David Hickish, Tamas Weaver, Andrew Gollins, Simon Wasan, Harpreet S.. Paul, James |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| author_browse | Allan, Karen Azzabi, Ashraf Boyd, Kathleen A.|||0000-0002-9764-0113 Bridgewater, John Briggs, Andrew H. Cassidy, Jim Cunningham, David Dhadda, Amandeep S. Ellis, Richard Essapen, Sharadah Falk, Stephen Farrugia, David Glimelius, B. Gollins, Simon Harkin, Andrea Hickish, Tamas Hollander, Niels Henrik Hughes, Rob Iveson, Timothy Kerr, Rachel S. McQueen, John Medley, Louise Olesen, Rene K. Paul, James Pearson, Sarah Propper, David Raouf, Sherif Rees, Charlotte Robles-Zurita, José Saunders, Mark P. Segelov, Eva Tabernero, Josep|||0000-0002-2495-8139 Wasan, Harpreet S.. Waterston, Ashita Weaver, Andrew Webb, Andrew Wilson, Charles |
| author_facet | Robles-Zurita, José Boyd, Kathleen A.|||0000-0002-9764-0113 Briggs, Andrew H. Iveson, Timothy Kerr, Rachel S. Saunders, Mark P. Cassidy, Jim Hollander, Niels Henrik Tabernero, Josep|||0000-0002-2495-8139 Segelov, Eva Glimelius, B. Harkin, Andrea Allan, Karen McQueen, John Pearson, Sarah Waterston, Ashita Medley, Louise Wilson, Charles Ellis, Richard Essapen, Sharadah Dhadda, Amandeep S. Hughes, Rob Falk, Stephen Raouf, Sherif Rees, Charlotte Olesen, Rene K. Propper, David Bridgewater, John Azzabi, Ashraf Farrugia, David Webb, Andrew Cunningham, David Hickish, Tamas Weaver, Andrew Gollins, Simon Wasan, Harpreet S.. Paul, James |
| author_role | author |
| collection | Dipòsit Digital de Documents de la UAB |
| description | The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken. The 3 M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3 M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3 M had lower QALYs than 6 M (not statistically significant). Overall, 3 M dominates 6 M with no significant detrimental impact on QALYs. The results provide the economic case that a 3 M treatment strategy should be considered a new standard of care. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_d0fe4947ef25821cda55da0a48b63cb4 |
| institution | Universitat Autònoma de Barcelona |
| instname_str | Universitat Autònoma de Barcelona |
| language | eng |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:ddd.uab.cat:214575 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| reponame_str | Dipòsit Digital de Documents de la UAB |
| spelling | SCOT a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer Robles-Zurita, José Boyd, Kathleen A.|||0000-0002-9764-0113 Briggs, Andrew H. Iveson, Timothy Kerr, Rachel S. Saunders, Mark P. Cassidy, Jim Hollander, Niels Henrik Tabernero, Josep|||0000-0002-2495-8139 Segelov, Eva Glimelius, B. Harkin, Andrea Allan, Karen McQueen, John Pearson, Sarah Waterston, Ashita Medley, Louise Wilson, Charles Ellis, Richard Essapen, Sharadah Dhadda, Amandeep S. Hughes, Rob Falk, Stephen Raouf, Sherif Rees, Charlotte Olesen, Rene K. Propper, David Bridgewater, John Azzabi, Ashraf Farrugia, David Webb, Andrew Cunningham, David Hickish, Tamas Weaver, Andrew Gollins, Simon Wasan, Harpreet S.. Paul, James Health care economics Economics Chemotherapy The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken. The 3 M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3 M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3 M had lower QALYs than 6 M (not statistically significant). Overall, 3 M dominates 6 M with no significant detrimental impact on QALYs. The results provide the economic case that a 3 M treatment strategy should be considered a new standard of care. https://ddd.uab.cat/record/214575 https://dx.doi.org/urn:doi:10.1038/s41416-018-0319-z |
| spellingShingle | SCOT Robles-Zurita, José Health care economics Economics Chemotherapy |
| title | SCOT |
| title_full | SCOT |
| title_fullStr | SCOT |
| title_full_unstemmed | SCOT |
| title_short | SCOT |
| title_sort | SCOT |
| topic | Health care economics Economics Chemotherapy |
| topic_facet | Health care economics Economics Chemotherapy |
| url | https://ddd.uab.cat/record/214575 https://dx.doi.org/urn:doi:10.1038/s41416-018-0319-z |